For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| 0.15 mg/kg IV Ketamine | Ketamine: Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes | 0 | None | 0 | 49 | 28 | 49 | View |
| 0.3 mg/kg IV Ketamine | Ketamine: Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes | 0 | None | 0 | 49 | 31 | 49 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Hearing Changes | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | None | View |
| Vision Changes | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Mood Alteration | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| Discomfort | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Hallucinations | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Headache | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Feeling of Unreality | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | None | View |